Stock in Focus: Provectus Biopharmaceuticals, In

Stock in Focus: Provectus Biopharmaceuticals, Inc. (OTC VCT)
By Justine Radlock -
January 20, 2017

Provectus Biopharmaceuticals, Inc. (OTC VCT) traded with the volume of 1.23 Million in the previous trading session. The Stock opened its session at $0 and closed at $0.02 by showing decrease of -4.07 percent. Provectus Biopharmaceuticals, Inc. has 1 year price target of $3.5. The stock gained a consensus recommendation of NA on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The company reported its last quarter on .

The 1 analysts offering 12-month price forecasts for Provectus Biopharmaceuticals Inc have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50. The median estimate represents a +21,112.12% increase from the last price of 0.02. (CNN MONEY)

Provectus Biopharmaceuticals, Inc. (OTC VCT) topped its 52-week high price of $0.54 on Apr 29, 2016 and 52-Week Low Price of $0.01 on Dec 21, 2016. The Stock currently has the market capitalization of $4.02 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 13.36% and monthly volatility of 21.57% respectively.

Provectus Biopharmaceuticals, Inc. Gross Margin percentage stands at 0% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of -33.49% with the 50-Day Simple Moving Average of -33.49 percent. Currently, the company has SMA200 (200-day simple moving average) of -91.81 Percent. The Stock has YTD (year to date) performance of -15.82 percent.

Many research firms have provided their ratings on Provectus Biopharmaceuticals, Inc. (OTC VCT) where Rodman & Renshaw provided Mkt Outperform rating on the stock on 7-Apr-09. Other firms include Rodman & Renshaw giving Mkt Perform rating on 27-Nov-07.

The latest Insider trade was made on 28 Mar 2016 where Wachter (Eric A) Chief Technology Officer did a transaction type “Buy” in which 106000 shares were traded at a price of $1. Another insider trade includes Director Koe (Jan E) who also initiated a transaction in which 100000 shares were traded on 28 Mar 2016 as “Buy”.

Company Profile:

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company’s product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!

Alway's searching for winners'